FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142322012> ?p ?o ?g. }

• W3142322012 endingPage "1946" @default.
• W3142322012 startingPage "1933" @default.
• W3142322012 abstract "Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels of fatty acid elongase 6 (ELOVL6) were lower in MM cells from BTZ-nonresponsive vs BTZ-responsive patients and in cultured MM cells selected for BTZ resistance compared with parental counterparts. Accordingly, depletion of ELOVL6 in parental MM cells suppressed BTZ-induced endoplasmic reticulum (ER) stress and cytotoxicity, whereas restoration of ELOVL6 levels in BTZ-resistant MM cells sensitized them to BTZ in tissue culture settings and, as xenografts, in a plasmacytoma mouse model. Furthermore, for the first time, we identified changes in the BTZ-induced lipidome between parental and BTZ-resistant MM cell lines underlying a functional difference in their response to BTZ. We demonstrated that restoration of ELOVL6 levels in BTZ-resistant MM cells resensitized them to BTZ largely via upregulation of ELOVL6-dependent ceramide species, which was a prerequisite for BTZ-induced ER stress and cell death in these cells. Our data characterize ELOVL6 as a major clinically relevant regulator of MM cell resistance to BTZ, which can emerge from the impaired ability of these cells to alter ceramide composition in response to BTZ." @default.
• W3142322012 created "2021-04-13" @default.
• W3142322012 creator A5003554962 @default.
• W3142322012 creator A5012484818 @default.
• W3142322012 creator A5015860985 @default.
• W3142322012 creator A5024693796 @default.
• W3142322012 creator A5046121518 @default.
• W3142322012 creator A5050138694 @default.
• W3142322012 creator A5050227848 @default.
• W3142322012 creator A5050601416 @default.
• W3142322012 creator A5051745395 @default.
• W3142322012 creator A5053603176 @default.
• W3142322012 creator A5054713779 @default.
• W3142322012 creator A5061257526 @default.
• W3142322012 creator A5067190256 @default.
• W3142322012 date "2021-04-06" @default.
• W3142322012 modified "2023-10-17" @default.
• W3142322012 title "The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma" @default.
• W3142322012 cites W1550062580 @default.
• W3142322012 cites W1577036326 @default.
• W3142322012 cites W1587397837 @default.
• W3142322012 cites W1864679135 @default.
• W3142322012 cites W1920908631 @default.
• W3142322012 cites W1963731318 @default.
• W3142322012 cites W1968798078 @default.
• W3142322012 cites W1969913835 @default.
• W3142322012 cites W1970504457 @default.
• W3142322012 cites W1978051650 @default.
• W3142322012 cites W1978058918 @default.
• W3142322012 cites W1980378700 @default.
• W3142322012 cites W1996253347 @default.
• W3142322012 cites W2010878528 @default.
• W3142322012 cites W2012216316 @default.
• W3142322012 cites W2014581910 @default.
• W3142322012 cites W2016274355 @default.
• W3142322012 cites W2026642838 @default.
• W3142322012 cites W2044052768 @default.
• W3142322012 cites W2046116275 @default.
• W3142322012 cites W2067253037 @default.
• W3142322012 cites W2068640275 @default.
• W3142322012 cites W2070645777 @default.
• W3142322012 cites W2073115843 @default.
• W3142322012 cites W2086453930 @default.
• W3142322012 cites W2093816724 @default.
• W3142322012 cites W2105375266 @default.
• W3142322012 cites W2107435587 @default.
• W3142322012 cites W2117629364 @default.
• W3142322012 cites W2121503734 @default.
• W3142322012 cites W2122834752 @default.
• W3142322012 cites W2129758120 @default.
• W3142322012 cites W2136338518 @default.
• W3142322012 cites W2144626362 @default.
• W3142322012 cites W2151152045 @default.
• W3142322012 cites W2170168836 @default.
• W3142322012 cites W2171504422 @default.
• W3142322012 cites W2177874257 @default.
• W3142322012 cites W2191007858 @default.
• W3142322012 cites W2259709654 @default.
• W3142322012 cites W2345368448 @default.
• W3142322012 cites W2408343565 @default.
• W3142322012 cites W2605439888 @default.
• W3142322012 cites W2606732388 @default.
• W3142322012 cites W2626955978 @default.
• W3142322012 cites W2766477555 @default.
• W3142322012 cites W2766900039 @default.
• W3142322012 cites W2769383666 @default.
• W3142322012 cites W2773382289 @default.
• W3142322012 cites W2790999714 @default.
• W3142322012 cites W2791971573 @default.
• W3142322012 cites W2795013773 @default.
• W3142322012 cites W2803622894 @default.
• W3142322012 cites W2809819252 @default.
• W3142322012 cites W2810166530 @default.
• W3142322012 cites W2894673810 @default.
• W3142322012 cites W2897589411 @default.
• W3142322012 cites W2911545095 @default.
• W3142322012 cites W2926343247 @default.
• W3142322012 cites W2931392716 @default.
• W3142322012 cites W2941461513 @default.
• W3142322012 cites W2952224031 @default.
• W3142322012 cites W2952646916 @default.
• W3142322012 cites W2953254812 @default.
• W3142322012 cites W2967638167 @default.
• W3142322012 cites W2974758394 @default.
• W3142322012 cites W2991704590 @default.
• W3142322012 cites W2999444248 @default.
• W3142322012 cites W4244540082 @default.
• W3142322012 doi "https://doi.org/10.1182/bloodadvances.2020002578" @default.
• W3142322012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8045499" @default.
• W3142322012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33821992" @default.
• W3142322012 hasPublicationYear "2021" @default.
• W3142322012 type Work @default.
• W3142322012 sameAs 3142322012 @default.
• W3142322012 citedByCount "9" @default.
• W3142322012 countsByYear W31423220122022 @default.
• W3142322012 countsByYear W31423220122023 @default.
• W3142322012 crossrefType "journal-article" @default.
• W3142322012 hasAuthorship W3142322012A5003554962 @default.

• next